{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAB+LA", "query": { "intervention": "CAB LA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAB+LA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T03:22:01.968Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03739996", "title": "Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Oral Cabotegravir (CAB)", "type": "DRUG" }, { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Long-Acting Injectable Cabotegravir (CAB LA)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC) ART", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2019-12-31", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 17, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739996" }, { "nct_id": "NCT06694805", "title": "A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA + RPV LA", "type": "DRUG" }, { "name": "Oral ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 326, "start_date": "2024-12-02", "completion_date": "2028-06-08", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06694805" }, { "nct_id": "NCT06970223", "title": "A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir long-acting", "type": "DRUG" }, { "name": "Lenacapavir long-acting", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2025-04-22", "completion_date": "2026-07-10", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06970223" }, { "nct_id": "NCT04692077", "title": "Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "MALE", "summary": "Up to 17 Years · Male only" }, "enrollment_count": 9, "start_date": "2020-02-19", "completion_date": "2023-07-07", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 4, "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04692077" }, { "nct_id": "NCT06451341", "title": "IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV" ], "interventions": [ { "name": "Acceptability of Intervention Measure (AIM)", "type": "BEHAVIORAL" }, { "name": "Intervention Appropriateness Measure (IAM)", "type": "BEHAVIORAL" }, { "name": "Feasibility of Intervention Measure (FIM)", "type": "BEHAVIORAL" }, { "name": "HIV Stigma Scale Questionnaire", "type": "BEHAVIORAL" }, { "name": "HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)", "type": "BEHAVIORAL" }, { "name": "HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)", "type": "BEHAVIORAL" }, { "name": "Needs and Barriers Assessment", "type": "BEHAVIORAL" }, { "name": "Pre-visit Outreach", "type": "BEHAVIORAL" }, { "name": "Qualitative interview - patient participants", "type": "BEHAVIORAL" }, { "name": "Staff education", "type": "BEHAVIORAL" }, { "name": "Staff Month 7 and 15 Survey - Staff Burden and Engagement", "type": "BEHAVIORAL" }, { "name": "Qualitative interview - staff", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 75, "start_date": "2024-07-01", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 4, "location_summary": "Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more", "locations": [ { "city": "Harlan", "state": "Iowa" }, { "city": "Shenandoah", "state": "Iowa" }, { "city": "Grand Island", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06451341" }, { "nct_id": "NCT02720094", "title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Oral Tablet", "type": "DRUG" }, { "name": "TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for cabotegravir oral tablet", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "Placebo for CAB LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4570, "start_date": "2016-12-19", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02720094" }, { "nct_id": "NCT06786520", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA", "type": "DRUG" }, { "name": "CAB ULA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2025-01-17", "completion_date": "2027-11-08", "has_results": false, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 3, "location_summary": "Mobile, Alabama • Coral Gables, Florida • Oak Brook, Illinois", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Oak Brook", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06786520" }, { "nct_id": "NCT05601128", "title": "A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection", "HIV Infections", "HIV I Infection" ], "interventions": [ { "name": "CAB + RPV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 12, "start_date": "2023-01-01", "completion_date": "2025-10-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05601128" }, { "nct_id": "NCT03635788", "title": "The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Standard of Care (SOC) Oral ART", "type": "DRUG" }, { "name": "Oral RPV", "type": "DRUG" }, { "name": "Oral CAB", "type": "DRUG" }, { "name": "RPV-LA Loading Dose", "type": "DRUG" }, { "name": "CAB-LA Loading Dose", "type": "DRUG" }, { "name": "RPV-LA Maintenance Dose", "type": "DRUG" }, { "name": "CAB-LA Maintenance Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 456, "start_date": "2019-03-28", "completion_date": "2026-08-30", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635788" }, { "nct_id": "NCT05979714", "title": "The Cheeky Study: A Novel Delivery System for CAB-RPV LA", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Patient-centered injection site", "type": "OTHER" }, { "name": "Patient-centered adherence support", "type": "BEHAVIORAL" }, { "name": "Provider education", "type": "OTHER" }, { "name": "Improved clinic communication strategies", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Public Health Foundation Enterprises, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2023-05-31", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2024-08-05", "last_synced_at": "2026-09-02T03:22:01.968Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05979714" } ] }